Cumulative incidence rates of the mucopolysaccharidoses in Germany

被引:296
作者
Baehner, F
Schmiedeskamp, C
Krummenauer, F
Miebach, E
Bajbouj, M
Whybra, C
Kohlschütter, A
Kampmann, C
Beck, M
机构
[1] Univ Mainz, Childrens Hosp, D-55101 Mainz, Germany
[2] Tech Univ Dresden, Fac Med, Dresden, Germany
[3] Univ Clin Eppendorf, Childrens Hosp, Hamburg, Germany
关键词
D O I
10.1007/s10545-005-0112-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to estimate the cumulative incidence rates of the mucopolysaccharidoses (MPS) in Germany, a retrospective epidemiological survey covering the period between 1980 and 1995 was implemented. Multiple ascertainment sources were used to identify affected patients. A prevalence of approximately 0.69 cases per 100 000 births was obtained for MPS I (Hurler phenotype). Within the study period, 4 patients with Hurler/Scheie phenotype and 7 cases with Scheie disease were detected. The cumulative incidence for MPS II (Hunter syndrome) was estimated as 0.64 cases per 100 000 births (1.3 cases per 100 000 male live births); that for MPS III (Sanfilippo syndrome types A, B and C) as 1.57 cases in 100 000 births; that for MPS IV A (Morquio syndrome) as 0.38 cases in 100 000; and that for MPS VI (Maroteaux-Lamy syndrome) as 0.23 cases per 100 000 births. Two cases of MPS IVB (beta-galactosidase deficiency) have been identified, but no patients with MPS VII or MPS IX. A relatively high number of patients with MPS IIIB, MPS IVA and MPS VI were of Turkish origin. The crude rate for all types of mucopolysaccharidoses is approximately 3.53 cases in 100 000 live births. The cumulative incidence pattern of MPS in Germany was compared with the corresponding rates among other industrial nations obtained from recent literature: the crude cumulative rates for all types of mucopolysaccharidoses (3.4-4.5 in 100 000 live births) were similar among all published populations; however, different frequencies of the various forms of MPS were observed.
引用
收藏
页码:1011 / 1017
页数:7
相关论文
共 24 条
[1]   Incidence of inborn errors of metabolism in British Columbia, 1969-1996 [J].
Applegarth, DA ;
Toone, JR ;
Lowry, RB .
PEDIATRICS, 2000, 105 (01) :art. no.-e10
[2]  
Breslow NE, 1987, STAT METHODS CANC RE, VII
[3]   MUCOPOLYSACCHARIDOSIS TYPE-I - IDENTIFICATION OF 13 NOVEL MUTATIONS OF THE ALPHA-L-IDURONIDASE GENE [J].
BUNGE, S ;
KLEIJER, WJ ;
STEGLICH, C ;
BECK, M ;
SCHWINGER, E ;
GAL, A .
HUMAN MUTATION, 1995, 6 (01) :91-94
[4]   MUCOPOLYSACCHARIDOSIS TYPE-I - IDENTIFICATION OF 8 NOVEL MUTATIONS AND DETERMINATION OF THE FREQUENCY OF THE 2 COMMON ALPHA-1-IDURONIDASE MUTATIONS (W402X AND Q70X) AMONG EUROPEAN PATIENTS [J].
BUNGE, S ;
KLEIJER, WJ ;
STEGLICH, C ;
BECK, M ;
ZUTHER, C ;
MORRIS, CP ;
SCHWINGER, E ;
HOPWOOD, JJ ;
SCOTT, HS ;
GAL, A .
HUMAN MOLECULAR GENETICS, 1994, 3 (06) :861-866
[5]   Selective screening of 10,000 high-risk Brazilian patients for the detection of inborn errors of metabolism [J].
Coelho, JC ;
Wajner, M ;
Burin, MG ;
Vargas, CR ;
Giugliani, R .
EUROPEAN JOURNAL OF PEDIATRICS, 1997, 156 (08) :650-654
[6]  
Cornel M C, 1999, Community Genet, V2, P162, DOI 10.1159/000016206
[7]   Enzyme replacement and enhancement therapies for lysosomal diseases [J].
Desnick, RJ .
JOURNAL OF INHERITED METABOLIC DISEASE, 2004, 27 (03) :385-410
[8]   HUMAN-GENETICS - JEWISH LYSOSOMES [J].
DIAMOND, JM .
NATURE, 1994, 368 (6469) :291-292
[9]  
Emre S, 2002, TURKISH J PEDIATR, V44, P13
[10]  
LOWRY RB, 1990, HUM GENET, V85, P389